MedTrace Logo

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-10-08

No results posted yet for this study

Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide may be an effective treatment for neuroendocrine tumors.

PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide works in treating patients with progressive neuroendocrine tumors.

Conditions

  • Gastrointestinal Carcinoid Tumor
  • Islet Cell Carcinoma

Interventions

DRUG

octreotide acetate

DRUG

vatalanib

PROCEDURE

anti-cytokine therapy

PROCEDURE

antiangiogenesis therapy

PROCEDURE

biological therapy

PROCEDURE

endocrine therapy

PROCEDURE

enzyme inhibitor therapy

PROCEDURE

growth factor antagonist therapy

PROCEDURE

hormone therapy

PROCEDURE

protein tyrosine kinase inhibitor therapy

PROCEDURE

somatostatin analogue therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Kyle Holen, MD · University of Wisconsin, Madison

  • Mary Mulcahy, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00227773 on ClinicalTrials.gov